Cimetidine Articles
SB Focuses On Restructuring And Growth
19 December 1994
Bayer Adapting Pharma Business
12 December 1994
Glaxo Files For OTC Zantac In USA
21 November 1994
Non-prescription Cimetidine In New Zealand
14 November 1994
OTC H2 Antagonists Dose Too Low
14 November 1994
Analysts Upgrade SmithKline Beecham
31 October 1994
USA's Top-Selling Drugs In 1993
24 October 1994
SB Sales Jump 8%, Fuelled By New Drugs
24 October 1994
Generics To Lead US Managed Care "Soon"
17 October 1994
SmithKline Beecham On Adapting To Change
10 October 1994
Eradication Therapy For Helicobacter Pylori
10 October 1994
Competition and Acquisition Pressure Hits Glaxo
19 September 1994
New York Stock Comment
19 September 1994
SmithKline Beecham To Acquire Sterling Winthrop
5 September 1994
Generic Drug Stocks - A Buying Opportunity
22 August 1994
Rx-to-OTC Switching Trends
22 August 1994
European Stock Comment
8 August 1994
FDA Balks At OTC-Switch Approvals; Blow To Makers
8 August 1994
TOKYO STOCK COMMENT
1 August 1994
NIPPON GLAXO PROGRAM TO MOVE ZANTAC TO OTC
1 August 1994
German Approvals Boost From EU
1 August 1994
FDA Warns Lilly Over Axid Claims
1 August 1994
The Gloves Are Off In Glaxo/Novopharm Dispute
1 August 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
Re-Engineering Japanese R&D - Again
25 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
GLAXO CLOSER TO OTC RANITIDINE
11 July 1994
OPPORTUNITIES IN SMALL- MID-CAP US DRUG STOCKS
4 July 1994
GENERIC TAGAMET LIQUID APPROVAL
13 June 1994
TAIWAN DRUG MARKET IN 1993
13 June 1994
BOOTS LOOKING MORE TO THE OTC SECTOR
13 June 1994
EXTRAORDINARY INCOME BOOSTS FUJISAWA IN 1994
30 May 1994
EUROPE STOCK COMMENT
23 May 1994
"REVOLUTION" IN EURO OTC DIGESTIVES
23 May 1994
FURTHER DEFENSIVE MOVES FROM SB OVER CIMETIDINE
23 May 1994
LEDERLE STANDARD PRODUCTS
23 May 1994
SB SETTLEMENT WITH NOVOPHARM/SCHEIN
23 May 1994
SB MOVES TO PROTECT OFF-PATENT TAGAMET
16 May 1994
EUROPEAN STOCK COMMENT
16 May 1994
AVALANCHE OF US PHARMA ACQUISITIONS?
9 May 1994
ANTIHISTAMINES HELP ANESTHESIA
2 May 1994
SMITHKLINE BEECHAM'S MIXED 1st QTR
2 May 1994
LILLY TO MARKET GENERIC TAGAMET
25 April 1994
LARGE DOWNSIDE FOR GLAXO SHARES
25 April 1994
PROSPECTS FOR DRUG PRICE CHANGES
18 April 1994
SMITHKLINE CORRECTION
21 March 1994
OTC TAGAMET LAUNCHED IN UK
14 March 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
THE FUTURE FOR THE US DRUG MARKET
28 February 1994
GYNECOMASTIA WITH ANTIULCERANTS
28 February 1994
PEPCID AVAILABLE OTC IN THE UK
28 February 1994
UK PRODUCT NEWS IN BRIEF
7 February 1994
SB RENAMES CONSUMER BRANDS
17 January 1994
EUROPEAN STOCK COMMENT
17 January 1994
UK OTC SWITCHES ON JANUARY 21
17 January 1994
EUROPE STOCK COMMENT
10 January 1994
IS THE WORST OVER FOR DRUG STOCKS?
20 December 1993
DIVERSIFICATION NOT THE PATH FOR GLAXO
13 December 1993
WORLD MARKETS FOR CNS AND GASTROINTESTINALS
13 December 1993
ALTANA PLANS DRUG INNOVATION OFFENSIVE
13 December 1993
CENTRA PLANNING 1994 FAMOTIDINE SWITCH
6 December 1993
GLAXO REAFFIRMS COMMITMENT TO R&D
6 December 1993
SMITHKLINE BEECHAM GIVING TAGAMET REBATES
15 November 1993
GENERIC CIMETIDINE WINS US APPROVAL
1 November 1993
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
ULCER DRUG MARKET DECLINE FORECAST
4 October 1993
US COURT UPHOLD GLAXO ZANTAC PATENT
27 September 1993
GLAXO RESULTS PLEASE, BUT CONCERNS PERSIST
20 September 1993
EUROPEAN STOCK COMMENT
20 September 1993
FDA PANEL OVERTURNS OTC TAGAMET HOPES
20 September 1993
ADAPTING TO A CHANGING DRUG IND ENVIRONMENT
20 September 1993
STRONG PERFORMANCE FROM GLAXO, AND ZANTAC
13 September 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
SELF MEDICATION TO PASS $27BILLION IN MAJOR MARKETS
23 August 1993
CIRCA'S 1ST PRODUCT APPROVED BY FDA
16 August 1993
WARNER-LAMBERT OTC DEALS ON ZOVIRAX, ZANTAC
2 August 1993
DRUG IND: CHANGING COST STRUCTURES
2 August 1993
DELISTING AND OTC SALES IN DENMARK
26 July 1993
EUROPEAN STOCK COMMENT
19 July 1993
TAGAMET A STEP NEARER TO OTC APPROVAL
12 July 1993
ROUND UP OF PRODUCT SWITCHES
12 July 1993
EUROPEAN STOCK COMMENT
12 July 1993
SMITHKLINE BEECHAM CORPORATE OTC STRATEGY
5 July 1993
FEVER WITH RANITIDINE
14 June 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
NET INCOME FALLS 77% IN 1992 AT FUJISAWA
31 May 1993
OTC GASTROINTESTINALS IN THE USA
24 May 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
STUDY ON H2 ANTAGONISTS AND ALCOHOL
12 April 1993
JOB CUTS AND EARNINGS WARNING FROM MERCK
5 April 1993
GLAXO BENDS TO FDA MISLEADING ADS REQUIREMENT
5 April 1993
SMITHKLINE RESOLVES PATENT DISPUTE
29 March 1993
SHOCK RESIGNATION OF GLAXO'S ERNEST MARIO
15 March 1993
GLOBAL SALES OF H2 BLOCKERS TO DECLINE?
1 March 1993
SB BEECHAM RESULTS; EXPLOITS STRENGTHS
1 March 1993
UK NHS PURCHASES OF "LOSS LEADERS"
1 March 1993
ULCER STUDY NO THREAT TO ULCER DRUG FIRMS
22 February 1993
GLAXO TO FILE FOR OTC ZANTAC IN 1994?
1 February 1993
GLAXO AND LILLY'S ULCER DRUGS OFF MEDI-CAL
18 January 1993
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
